Glycated albumin and direct low density lipoprotein cholesterol levels in type 2 diabetes mellitus

Clinica Chimica Acta

Volumn 406, Issue 1-2, 2009, Pages 71-74

  Ai, Masumi ^a,b   Otokozawa, Seiko ^a,b   Schaefer, Ernst J ^a,b   Asztalos, Bela F ^a,b   Nakajima, Katsuyuki ^a,b   Shrader, Peter ^c   Kathiresan, Sekar ^c,e   Meigs, James B ^c,e   Williams, Gordon ^d,e   Nathan, David M ^c,e  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Glycated albumin; Low density lipoprotein cholesterol; Type 2 diabetes

Indexed keywords

GLUCOSE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RACE;

AGE FACTORS; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; CONTINENTAL POPULATION GROUPS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; SERUM ALBUMIN; SEX FACTORS;

EID: 67650241728     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.05.015     Document Type: Article

References (27)

1. Expert Panel Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 285 (2001) 2486-2497
2. Collins R., Armitage J., Parish S., Sleigh P., Peto, and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial. Lancet 362 (2003) 2005-2016
3. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Lancet 364 (2004) 685-696
4. Shepherd J., Barter P., Carmena R., et al. Effects of lowering low density lipoprotein cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. Diabetes Care 29 (2006) 1220-1226
5. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
6. Nathan D.M., Crofford O.B., Genuth S., et al., for the DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: The Diabetes Control and Complications Trial. N Engl J Med 329 (1993) 978-986
7. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular disease in Japanese patients with non-insulin dependent diabetes: a randomized prospective six year study. Diabetes Res Clin Pract 928 (1995) 103-117
8. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2355
9. American Diabetes Association. Standards of medical care. Diabetes Care 33 suppl1 (2007) 13-25
10. Nathan D.M., Singer D.E., Hurxthal K., and Goodson J.D. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 310 (1984) 341-346
11. Little R.R., Rohlfing C.L., Wiedmeyer H.M., Myers G.L., Sacks D.B., and Goldstein D.E. The National Glycohemoglobin Standardization Program (NGSP): a five-year progress report. Clin Chem 47 (2001) 1985-1992
12. Schaefer E.J., Audelin M.C., McNamara J.R., et al. Comparison of fasting and postprandial plasma lipoproteins in subjects with and without coronary heart disease. Am J Cardiol 88 (2001) 1129-1133
13. Sugiuchi H., Uji Y., Okabe H., et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 41 (1995) 717-723
14. Sugiuchi H., Irie T., Yoshinori U., et al. Homogeneous assay for measuring low-density lipoprotein cholesterol in serum with triblock copolymer and alpha-cyclodextrin. Clin Chem 44 (1998) 522-531
15. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
16. McNamara J.R., Cohn J.S., Wilson P.W.F., and Schaefer E.J. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem 36 (1990) 36-42
17. Kouzuma T, Uematsu Y, Usami T, Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 346:135-143.
18. Chujo K., Shima K., Tada H., Oohashi T., Minakuchi J., and Kawashima S. Indicators for blood glucose control in diabetics with end-stage chronic renal disease: GHb vs. glycated albumin (GA). J Med Invest 53 (2006) 223-228
19. McNamara J.R., Cole T.G., Contois J.H., Ferguson C.A., Ordovas J.M., and Schaefer E.J. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem 41 (1995) 232-240
20. Siegel R.D., Cupples A., Schaefer E.J., and Wilson P.W.F. Lipoproteins, apolipoproteins, and low density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism 45 (1996) 1267-1272
21. Schaefer E.J., McNamara J.R., Shah P.K., et al. Elevated remnant-like particle cholesterol and triglyceride levels in diabetic men and women in the Framingham Offspring Study. Diabetes Care 25 (2002) 989-994
22. Schaefer E.J., McNamara J.R., Tayler T., et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 90 (2002) 689-696
23. Schaefer E.J., McNamara J.R., Tayler T., et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93 (2004) 31-39
24. Inaba M., Okuno S., Kumeda Y., et al., Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycosylated hemoglobin in hemodialysis patients with diabetes: effects of anemia and erythropoietin. J Am Soc Nephrology 18 (2007) 896-903
25. Pu L.J., Lu L., Xu X.W., et al. Value of glycated albumin and high sensitivity C reactive protein in predicting the presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 5 (2006) 2480-2485
26. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.D. Advanced glycation endproducts: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
27. Wiernsperger N.F. Oxidative stress: the special case of diabetes. Biofactors 19 (2003) 11-18